Ensysce Biosciences Plans To Implement 1-For-15 Reverse Split Of Its Common Stock, Effective December 6, 2024
Ensysce Biosciences Plans To Implement 1-For-15 Reverse Split Of Its Common Stock, Effective December 6, 2024
Ensysce生物科技計劃在2024年12月6日實施1比15的普通股逆向拆分。
The Company's common stock will begin trading on a split-adjusted basis when the market opens on December 6, 2024, under its current trading symbol "ENSC". The new CUSIP number of the Company's common stock following the reverse stock split will be 293602 504.
公司的普通股將從2024年12月6日市場開盤時開始以經過分拆調整的方式交易，在其當前交易標的"ENSC"。公司普通股在進行股票逆向拆分後的新CUSIP編號將爲293602 504。
The reverse stock split is intended, among other things, primarily to increase the bid price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market.
進行股票逆向拆分的主要目的之一是提高公司普通股的買盤價格，以使公司能夠再次符合納斯達克資本市場上持續上市所需的每股最低買盤價格要求爲1.00美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間